Trial · NCT07903922
Continuous Blood Pressure Variability and Small Vessel Disease in Acute Ischemic Stroke
NCT07903922, Recruiting, Minyoul Baik
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Continuous Blood Pressure Variability and Small Vessel Disease in Acute Ischemic Stroke. Trials, record NCT07903922. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07903922
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Continuous Blood Pressure Variability and Small Vessel Disease in Acute Ischemic Stroke
- NCT number
- NCT07903922
- Status
- Recruiting
- Enrollment
- 450 participants, estimated
- Lead sponsor
- Minyoul Baik
- Conditions
- Ischemic Stroke, Acute, Blood Pressure Variability, Cerebral Small Vessel Disease, White Matter Hyperintensity
- Interventions
- Cuffless ring-type continuous blood pressure monitor
- First posted
- 2026-10-29
- Last updated
- 2026-11-12
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Poor functional outcome (modified Rankin Scale 3-6) at discharge | At discharge or transfer from the neurology service, whichever occurs first (an average of 7 days) | Functional outcome measured by the modified Rankin Scale (mRS), a 7-level scale from 0 (no symptoms) to 6 (death). Poor outcome is defined as mRS 3-6 versus good outcome mRS 0-2, assessed at hospital discharge. The primary analysis relates this outcome to systolic blood pressure variability (standard deviation) over the first 72 hours. |
| Secondary | Ordinal modified Rankin Scale at the end of admission | At discharge or transfer from the neurology service, whichever occurs first (an average of 7 days) | Full distribution of the modified Rankin Scale (0-6) at the end of the acute neurology admission, analyzed in relation to blood pressure variability metrics. |
| Secondary | Early neurological deterioration during hospitalization | During the acute neurology admission (an average of 7 days) | Early neurological deterioration, defined as an increase of 2 or more points in the NIHSS during the acute admission. |
| Secondary | Parenchymal hematoma during hospitalization | During the acute neurology admission (an average of 7 days) | Parenchymal hematoma on follow-up imaging, classified by the ECASS radiologic criteria (PH1 or PH2), during the acute neurology admission. |
| Secondary | Poor functional outcome (modified Rankin Scale 3-6) at 3 months | 90 days after stroke onset | Functional outcome is measured by the modified Rankin Scale (mRS), a 7-level scale ranging from 0 (no symptoms) to 6 (death). A poor outcome is defined as an mRS score of 3-6, compared to a good outcome of 0-2, evaluated at 3 months post-stroke if follow-up data are available. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07903922
GET https://conductscience.org/api/trials/v1/NCT07903922/registered